Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products (NCT04183491), a randomized phase 1 study. The primary outcome is Area Under Effect Curve (AUEC) for Neopterin for Interferon Beta-1a and Peginterferon Beta-1a.

2. Clinical Question

The study asks how neopterin and other pharmacodynamic biomarkers respond across dose groups for interferon beta-1a and peginterferon beta-1a in healthy subjects. Its stated aim is to characterize pharmacokinetics and pharmacodynamics across an appropriate dose range and inform operating characteristics for future pharmacodynamic similarity studies. It is not a clinical-outcome trial, and the posted endpoint results do not constitute a finding of biosimilarity or equivalence.

3. Trial Design

The registry describes a completed Phase 1, randomized, double-masked, parallel-arm, placebo-controlled, single-dose study. The planned enrollment was 84 healthy subjects. The groups covered low, intermediate, and high doses of interferon beta-1a and peginterferon beta-1a, along with placebo. Interferon beta-1a was given intramuscularly and peginterferon beta-1a subcutaneously. The randomization method, allocation concealment procedures, and details of how masking was maintained are not reported in the registry record.

The posted primary endpoint results include arm-level means and standard deviations for the six active-dose groups. Their reported sample sizes range from 11 to 12. The placebo arm is part of the design, but a placebo result is not reported for this primary endpoint in the registry record. The primary analysis population is described as subjects who did not discontinue before study end; details of the handling of discontinuations are not reported.

Neopterin was measured repeatedly after dosing. The listed early collection times run from 0 through 72 hours post-dose, followed by once-daily measurement from Day 4 onward. The registry specifies follow-up until 7 days post-dose for interferon beta-1a arms and 14 days post-dose for peginterferon beta-1a arms. These unequal follow-up windows matter when interpreting an accumulated response measure: results summarize biomarker response over the respective specified windows, rather than over a common duration.

The record lists pharmacokinetic outcomes, additional biomarker outcomes, and pharmacodynamic model parameters as secondary measures. It does not report the protocol’s original sample-size rationale, planned interim analyses, or detailed statistical analysis plan.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Only the first 6 of 7 groups are shown.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Analysis population includes all subjects who did not discontinue before the end of study.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Only the first 6 of 8 groups are shown.

6. Primary Endpoint

The registry lists the primary outcome as Area Under Effect Curve (AUEC) for Neopterin for Interferon Beta-1a and Peginterferon Beta-1a, measured over 0, 1, 3, 6, 8, 16, 24, 32, 40, 48, 72, hours post-dose; once daily from Day 4 onwards until 7 days post-dose for Interferon Beta-1a treatment arms (Arms A, B and C) and 14 days post-dose for Peginterferon Beta-1a treatment arms (Arms D, E, and F).

The primary endpoint is the area under the effect curve for neopterin, expressed in ng*day/mL. The registry defines the measure as baseline-subtracted and reports its mean and standard deviation at the low, intermediate, and high doses of each product. Repeated measurements after dosing contribute to this accumulated measure, so it represents the response over time rather than a single measurement at a particular visit.

Pharmacodynamic biomarkers can help characterize how a biological response changes with dose. In this study, neopterin was selected as a standard pharmacodynamic metric to describe responses across the studied dose range. That makes it relevant to the stated purpose of informing design characteristics for future pharmacodynamic similarity studies. It does not make the measure a direct clinical outcome, nor does it establish that the products are similar in clinical benefit or safety.

The observation schedule differs by product: interferon beta-1a was followed through 7 days post-dose, whereas peginterferon beta-1a was followed through 14 days post-dose. The registry does not report the numerical integration procedure used to calculate the area under the effect curve, how measurements outside the scheduled times were handled, or whether any alternative endpoint definitions were examined. Those details would help readers assess precisely how the repeated measurements were reduced to the posted summary.

7. Results Posted in the Registry

• Arm B: Interferon Beta-1a Intermediate Dose: mean 9.61 versus 7.82 on control; difference 1.79 (95% CI -0.64 to 4.22), standardized effect d = 0.59; z-test p = 0.149.
• Arm C: Interferon Beta-1a High Dose: mean 11.08 versus 7.82 on control; difference 3.26 (95% CI -0.33 to 6.85), standardized effect d = 0.76; z-test p = 0.075.
• Arm D: Peginterferon Beta-1a Low Dose: mean 11.52 versus 7.82 on control; difference 3.70 (95% CI -1.07 to 8.47), standardized effect d = 0.62; z-test p = 0.128.
• Arm E: Peginterferon Beta-1a Intermediate Dose: mean 18.20 versus 7.82 on control; difference 10.38 (95% CI 5.14 to 15.62), standardized effect d = 1.59; z-test p = <0.001.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Area Under Effect Curve (AUEC) for Myxovirus-resistance Protein A (MxA) for Interferon Beta-1a and Peginterferon Beta-1a

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Arm B: Interferon Beta-1a Intermediate Dose: mean 172.00 versus 140.00 on control; difference 32.00 (95% CI -31.09 to 95.09), standardized effect d = 0.41; z-test p = 0.320.
  • Arm C: Interferon Beta-1a High Dose: mean 211.00 versus 140.00 on control; difference 71.00 (95% CI 0.97 to 141.03), standardized effect d = 0.85; z-test p = 0.047.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Arm B: Interferon Beta-1a Intermediate Dose and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval excludes no difference, so the mean is statistically higher for Arm C: Interferon Beta-1a High Dose than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

Maximum Change From Baseline for Myxovirus-resistance Protein A (MxA) for Interferon Beta-1a and Peginterferon Beta-1a

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Arm B: Interferon Beta-1a Intermediate Dose: mean 62.90 versus 52.90 on control; difference 10.00 (95% CI -14.19 to 34.19), standardized effect d = 0.33; z-test p = 0.418.
  • Arm C: Interferon Beta-1a High Dose: mean 73.40 versus 52.90 on control; difference 20.50 (95% CI -6.03 to 47.03), standardized effect d = 0.64; z-test p = 0.130.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Arm B: Interferon Beta-1a Intermediate Dose and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Arm C: Interferon Beta-1a High Dose and the control. The interval gives the range of effects that remain compatible with the data.

The posted numerical secondary summaries concern MxA AUEC and maximum change from baseline for MxA. Across the active-dose groups, both measures have higher observed means at higher doses within each product, with larger values in the peginterferon beta-1a arms. The standard deviations also show substantial variability, particularly in the peginterferon beta-1a groups. These are descriptive patterns rather than a separate basis for concluding that one product is better or more similar to the other.

The MxA measures add context to the primary neopterin result because they describe other pharmacodynamic responses to the same products and dose groups. A broadly increasing pattern across biomarkers is useful for characterizing the response range, but it does not independently validate the neopterin result or establish a consistent dose-response model. The MxA measures use different scales and capture different aspects of response, so their numerical values are not directly comparable with neopterin AUEC.

The registry lists additional pharmacokinetic and pharmacodynamic outcomes, including concentration measures and neopterin model parameters. Numerical results for those listed measures are not reported in the registry record. The available secondary findings should therefore be interpreted as an incomplete view of the broader outcome set, rather than as a comprehensive assessment of all registered measures.

Unadjusted secondary comparisons carry less weight because the record does not report a multiplicity plan or adjusted inferential results. When many outcomes, doses, and contrasts are considered, some apparently notable results can arise by chance. The secondary summaries are most useful as descriptive biomarker information and as context for future study planning. They should not override the primary endpoint interpretation or be treated as confirmatory evidence across the full set of registered outcomes.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Area Under the Curve (AUC) for Interferon Beta-1a and Peginterferon Beta-1a
• Maximum Concentration (Cmax) for Interferon Beta-1a and Peginterferon Beta-1a
• Area Under Effect Curve (AUEC) for Myxovirus-resistance Protein A (MxA) for Interferon Beta-1a and Peginterferon Beta-1a
• Maximum Change From Baseline for Myxovirus-resistance Protein A (MxA) for Interferon Beta-1a and Peginterferon Beta-1a
• Pharmacodynamic Model Parameter, Emax (Maximum Effect), for Neopterin Area Under the Effect Curve Models With Interferon Beta-1a or Peginterferon Beta-1a
• Pharmacodynamic Model Parameter, ED50 (Half Maximal Effect Dose), for Neopterin Area Under the Effect Curve Models With Interferon Beta-1a or Peginterferon Beta-1a
• Pharmacodynamic Model Parameter, Emax, for Neopterin Maximum Change From Baseline Models With Interferon Beta-1a or Peginterferon Beta-1a
• Pharmacodynamic Model Parameter, ED50, for Neopterin Maximum Change From Baseline Models With Interferon Beta-1a or Peginterferon Beta-1a

9. Statistical Interpretation

10. Statistical Methods Explained

The primary outcome is continuous, and the registry reports a mean and standard deviation for each active-dose arm. The comparison summaries are unadjusted mean differences against the low-dose interferon beta-1a reference. No formal analysis results are reported in the registry record. The explanations below describe general statistical concepts and how they apply to the posted summaries.

What does a mean summarize?

In general, a mean gives the arithmetic average of observed values in a group. It provides a concise description of the group’s location, but it does not show the full distribution. Two groups can have similar means while differing in their spread or in the shape of their distributions. Here, the arm means summarize baseline-subtracted neopterin AUEC, a continuous measure accumulated across post-dose observations.

In general, the standard deviation describes how dispersed individual observations are around their group mean. A larger standard deviation indicates greater variability among the observed values. It is not the same as the standard error of a mean, which describes the sampling uncertainty of the estimated mean. The standard deviations reported for the peginterferon beta-1a groups are larger than those reported for the interferon beta-1a groups, so the degree of within-arm variability should be considered when comparing the means. A mean alone cannot show whether the observed values are tightly clustered or widely dispersed.

What does a mean difference describe?

In general, a mean difference expresses the estimated separation between the mean in a comparison group and the mean in its reference group, on the original outcome scale. A positive difference in these comparisons means that the comparison arm’s posted mean is higher than the mean in the low-dose interferon beta-1a reference arm. The estimate does not, on its own, indicate whether the difference is precise or clinically important. Its uncertainty is conveyed by a confidence interval, and its scale is interpretable in the endpoint’s units.

The comparison set does not use placebo as the reference. This distinction matters: a contrast against an active low-dose arm answers a different question from a contrast against placebo. The posted contrasts also do not directly compare interferon beta-1a with peginterferon beta-1a at matched dose levels. The doses and routes differ, and the endpoint follow-up windows differ by product.

How should confidence intervals be read?

In general, a confidence interval gives a range of values compatible with the estimate and the statistical procedure used, reflecting sampling uncertainty. A narrower interval indicates greater precision than a wider interval. If an interval for a mean difference includes zero, the data are compatible with no mean difference as well as with values on either side of zero under the interval procedure. If it excludes zero, the interval indicates a difference at the corresponding confidence level under that procedure. An interval is not a guarantee that the true value lies inside it, and it does not account automatically for bias, missing data, or multiple testing.

For the primary comparisons, the reported intervals for intermediate-dose and high-dose peginterferon beta-1a exclude zero. The intervals for intermediate-dose interferon beta-1a, low-dose peginterferon beta-1a, and high-dose interferon beta-1a include zero. This reading concerns each unadjusted comparison individually. It should not be treated as a family-wide conclusion because the registry does not report a multiplicity procedure.

Why does variability matter?

In general, greater variability makes it harder to estimate a group mean precisely when other aspects of the design are held constant. A pooled standard deviation can be used in a standardized comparison or in a planning calculation, but it is not a substitute for considering the original-unit means and standard deviations. The arm-level standard deviations differ notably, so a simple standardized effect description should not replace examination of the outcome-scale summaries. The registry does not report a model that adjusts for covariates or accounts for any particular distributional feature.

Over-dispersion is a general concern when observed variability is greater than a statistical model assumes. A model that understates variability may produce overly narrow intervals or overly optimistic tests. The registry record does not report a model-based analysis for the primary outcome, so it is not possible to determine from the record whether such a model was used or how its assumptions were checked.

What does an unadjusted p-value tell the reader?

In general, a p-value describes how unusual data at least as incompatible with a specified null hypothesis would be if that hypothesis and the test assumptions were correct. It is not the probability that the null hypothesis is true, and it does not measure the size or importance of a difference. The listed p-values are unadjusted comparisons. Because several doses and outcomes are involved, interpreting each p-value as if it were the sole planned test can overstate the evidence across the full set of questions. The registry does not report the prespecified testing strategy or any adjustment for multiple comparisons.

The statistical summaries are based on small arm-level samples, with reported group sizes of 11 or 12 for the primary outcome. Such summaries can be imprecise and sensitive to the observed values. The registry’s stated analysis population excludes subjects who discontinued before the end of the study, but the number excluded, reasons for discontinuation, and missing-data methods are not reported in the registry record. These omissions limit evaluation of how representative the posted estimates are of all randomized subjects.

11. Confidence Intervals and Precision

Precision is best judged from the confidence intervals for the mean differences, not from the mean estimates or p-values alone. A confidence interval describes uncertainty around an estimated contrast under the statistical procedure used. A wide interval allows a broader range of plausible differences and signals less precision. An interval that includes zero does not establish that the groups are equal; it indicates that the reported data do not narrowly distinguish the contrast from zero using that interval procedure.

For the primary endpoint, the interval for intermediate-dose interferon beta-1a ranges from -0.642 to 4.222, and its unadjusted p-value is 0.149. The high-dose interferon beta-1a interval includes zero, with p = 0.075. The low-dose peginterferon beta-1a interval also includes zero, with p = 0.128. In contrast, the intermediate-dose peginterferon beta-1a interval ranges from 5.143 to 15.62, and the high-dose peginterferon beta-1a interval ranges from 4.671 to 22.87; their unadjusted p-values are < 0.001 and 0.003, respectively. The high-dose interferon beta-1a interval has an endpoint reported to four decimal places, so it is not reproduced.

Even intervals that exclude zero can be wide enough to leave substantial uncertainty about the size of the contrast. These intervals are unadjusted and do not incorporate a reported multiplicity correction. The small arm-level samples and the observed variability further counsel against treating a statistically distinct estimate as a precise estimate of the underlying response. The registry does not report confidence intervals for the arm means themselves or a sponsor analysis that could clarify the inferential procedure.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

Read each planning entry as participants per arm for the stated power level and assumed effect fraction. The figures are planning illustrations based on the observed effect, not the trial’s original design rationale. For these continuous-outcome comparisons, the assumptions are a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. The assumed effect is the stated fraction of the observed effect. These figures are participants per arm, not total participants. The note about total events applies to time-to-event planning; this endpoint is continuous.

The 80% power column gives the estimated participants per arm for a planning scenario designed to have an 80% chance of detecting the assumed effect under the stated assumptions, if that effect and assumptions hold. The 90% power column gives the corresponding estimate for a higher chance of detection. Higher target power generally requires more participants under otherwise unchanged assumptions. The figures are not observed power, and they do not show the probability that a result is true.

Each row uses an effect fraction: 100% of the observed effect, 75% of the observed effect, or 50% of the observed effect. Smaller assumed effects require more participants. For example, the primary comparison for intermediate-dose peginterferon beta-1a has estimates of 7 participants per arm for 80% power and 9 for 90% power when planning for 100% of the observed effect. Planning for 75% of that effect gives 12 and 15, respectively; planning for 50% gives 25 and 34. These are illustrations of the assumptions, not enrollment recommendations or evidence that the trial had a particular power.

The registry’s own design assumptions, including its original sample-size justification, are not reported in the registry record. The planning estimates should therefore be read as hypothetical comparisons based on observed effects, rather than as a reconstruction of the trial’s planning process.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, Δ is the difference in means to detect and σ is the common standard deviation.

Worked calculation for this trial

1. Observed difference Δ = 1.790; pooled standard deviation σ = 3.039.
2. n = 2 × (1.96 + 0.842)² × 3.039² / 1.790² = 45.3, rounded up to 46 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
delta <- 1.79                      # observed difference in means
sigma <- 3.03948186373928                     # pooled standard deviation
n_per_arm <- function(power, frac = 1) {
  ceiling(round(2 * (z_a + qnorm(power))^2 * sigma^2 / (delta * frac)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (t-based, so very slightly larger)
cat("power.t.test:", round(power.t.test(delta = delta, sd = sigma, power = 0.80)$n, 1), "\n")

# Simulation: exact two-sample t-test using simulated means and variances
set.seed(4183491)
n    <- n_per_arm(0.80)
reps <- 20000
m_diff <- rnorm(reps, delta, sigma * sqrt(2 / n))             # difference in sample means
s2     <- sigma^2 * rchisq(reps, 2 * (n - 1)) / (2 * (n - 1))   # pooled sample variance
tstat  <- m_diff / sqrt(s2 * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(tstat) > qt(0.975, 2 * (n - 1))), reps))

Output from running the code

100% of observed effect: n per arm = 46 (80% power), 61 (90% power)
 75% of observed effect: n per arm = 81 (80% power), 108 (90% power)
 50% of observed effect: n per arm = 182 (80% power), 243 (90% power)
power.t.test: 46.2 
Simulated power at n = 46 per arm: 0.795 (20000 replicates)

The simulation draws many sets of group means and variances at the planned sample size and counts how often the two-sample t-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Multiplicity, Missing Data and Analysis Populations

The study involves multiple dose groups, more than one product, and several registered pharmacokinetic and pharmacodynamic outcomes. Each additional comparison creates another opportunity for a nominally notable result to occur by chance. In general, multiplicity procedures control the chance of false-positive conclusions across a defined family of tests, or otherwise specify how results should be interpreted when many tests are performed.

The posted primary comparisons are unadjusted. The registry does not report a prespecified hierarchy of hypotheses, a family of primary contrasts, or a multiplicity adjustment. It also does not report whether any analyses were planned sequentially or whether an interim analysis was conducted. Consequently, the individual p-values should not be read as if they necessarily control the false-positive risk across all doses and outcomes. The registry record does not report formal analysis results from the sponsor.

The primary analysis population includes subjects who did not discontinue before the end of the study. The record does not report how many randomized subjects discontinued, which arms they were in, why they discontinued, or whether excluded subjects differed from those analyzed. Details of missing measurements, imputation, sensitivity analyses, and the treatment of measurements collected outside scheduled windows are not reported in the registry record. Without those details, it is not possible to assess whether the endpoint summaries could be affected by missingness or exclusions.

The record also does not give the original sample-size assumptions, a protocol-based power calculation, or the analysis model used by the study team. The planning illustrations calculated from observed effects are not a replacement for these design details. These limitations leave uncertainty about the intended confirmatory questions and how the study’s analysis addressed the several outcomes and comparisons.

15. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent non-serious adverse event terms

The registry reports 0 serious adverse events in each listed arm. The serious-event at-risk count is 12 in each arm. These figures describe the serious adverse event counts recorded during the study; they do not establish that a treatment has no serious risks. The study involved a limited group of healthy subjects, and the registry record does not provide event-specific serious adverse event terms.

The record also reports other adverse events affecting 7 subjects in the low-dose interferon beta-1a arm, 7 in the intermediate-dose interferon beta-1a arm, 10 in the high-dose interferon beta-1a arm, 7 in the low-dose peginterferon beta-1a arm, 9 in the intermediate-dose peginterferon beta-1a arm, 11 in the high-dose peginterferon beta-1a arm, and 4 in the placebo arm. These are separate from the serious adverse event figures, and the registry does not provide the event terms in the details available for this summary. Counts should be read as descriptive observations, not as comparative evidence of safety.

16. What the Result Does, and Does Not, Mean

The posted results describe biomarker responses after a single dose in healthy subjects. The primary endpoint is an accumulated, baseline-subtracted measure of neopterin response. Its arm means generally rise across the studied dose levels within each product. The unadjusted comparisons against the low-dose interferon beta-1a reference show different levels of precision: some intervals include zero, while the intermediate- and high-dose peginterferon beta-1a intervals exclude zero.

These findings do not establish a clinical benefit or lack of benefit. Neopterin AUEC and the listed secondary biomarkers are pharmacodynamic measures, not clinical outcomes. The study does not report patient outcomes or longer-term treatment effects. It also does not establish safety beyond the adverse-event observations recorded for this study.

The results do not establish biosimilarity or equivalence. A similarity assessment requires a defined comparison framework and an analysis designed to evaluate similarity, including appropriate margins and prespecified methods. Those details are not reported in the registry record. The posted primary comparisons use the low-dose interferon beta-1a arm as a reference; they are not direct matched-dose comparisons between the two products. The products were administered by different routes, at different dose amounts, and their AUEC observation windows differed.

Nor should a small unadjusted p-value be interpreted as proof of a large or important effect. The estimated contrast, its confidence interval, variability, analysis population, and multiplicity context all matter. The registry’s sample-size illustrations are based on observed effects and are not observed power or evidence that the original study was designed to detect a particular difference.

The most defensible reading is that the record provides descriptive pharmacodynamic information across dose groups, with uncertainty around individual contrasts and important limitations in the reported analysis details. The study’s stated purpose was to inform operating characteristics for future pharmacodynamic similarity studies. Whether these observations accomplish that purpose in a particular future design depends on assumptions and evidence not reported in the registry record.

17. Why This Trial Matters Statistically

This study is statistically informative because it measures repeated biomarker responses across dose ranges for two related biological products, rather than relying on a single post-dose observation. An accumulated endpoint such as neopterin AUEC can represent the pattern of response over time and may help characterize how a pharmacodynamic signal varies with dose. The additional MxA measures broaden the descriptive picture of biomarker response.

The design also illustrates why endpoint definition and observation windows matter. Interferon beta-1a and peginterferon beta-1a were followed for different durations, so their accumulated responses summarize different time intervals. Comparisons across products should take that into account rather than treating the endpoint values as directly interchangeable. Likewise, a reference-arm mean difference answers a narrower question than a direct product-to-product similarity analysis.

The arm-level sample sizes are small, and the standard deviations indicate meaningful variability, especially for peginterferon beta-1a. That combination makes precision and transparent reporting important. Confidence intervals show uncertainty more clearly than a threshold reading of p-values alone. The lack of reported multiplicity procedures and detailed analysis methods also demonstrates why exploratory biomarker results should be distinguished from confirmatory conclusions.

Finally, the registry’s planning illustrations show how assumptions about the effect size influence sample-size estimates. They are based on observed effects and should not be confused with the trial’s original design assumptions. This distinction is central when using an early pharmacodynamic study to inform later research: observed estimates can guide planning, but uncertainty and possible overestimation of effects must remain part of the interpretation.

18. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The study enrolled healthy subjects, so its biomarker summaries do not directly describe responses in a patient population. The registry record does not report detailed demographic characteristics or enough eligibility information to assess how broadly the results might generalize. The study used single doses, and the record does not report clinical outcome follow-up.

The primary endpoint is accumulated over different follow-up windows for the two products: 7 days post-dose for interferon beta-1a and 14 days post-dose for peginterferon beta-1a. That difference limits direct interpretation of cross-product AUEC comparisons. The registry does not report the numerical integration method or detailed handling of missing or off-schedule measurements.

Primary outcome results are available for the six active-dose groups, while a primary placebo result is not reported in the registry record. The posted mean-difference comparisons use the low-dose interferon beta-1a arm as their reference. They do not directly compare the two products at matched doses, and the different dose amounts and administration routes add further interpretive constraints.

Arm-level samples are small, and reported variability is substantial in some groups. The comparison p-values are unadjusted, while the record does not report a multiplicity strategy, formal sponsor analysis, or detailed model assumptions. The analysis population excludes subjects who discontinued before study end, but the numbers excluded and missing-data procedures are not reported. Original sample-size justification and interim-analysis information are also not reported in the registry record. Together, these gaps limit assessment of precision, potential bias, and the intended scope of inference.

19. Related Tutorials

20. Related Statistical Calculators

21. Sources

• ClinicalTrials.gov: Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products — NCT04183491.
• Registry record last updated 2024-04-22; status last verified 2023-11.
• Results first posted 2024-04-22.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

22. Record Summary

This completed Phase 1 study was randomized, double-masked, parallel-arm, placebo-controlled, and single-dose. It enrolled 84 healthy subjects to study interferon beta-1a and peginterferon beta-1a across low, intermediate, and high dose groups. The primary endpoint was baseline-subtracted neopterin AUEC, reported as arm means and standard deviations.

The observed primary means generally increased across dose groups within each product. Unadjusted mean-difference comparisons used low-dose interferon beta-1a as the reference; the precision of those comparisons varied. Results describe pharmacodynamic responses and do not establish clinical benefit, safety, or biosimilarity. Multiplicity procedures, detailed analysis methods, the original sample-size rationale, and missing-data methods are not reported in the registry record.